Top journals
Frequent coauthors
- Aisu Y 1
- Junzo Hamanishi 1
- Ken Yamaguchi 1
- Mandai M 1
- Murakami R 1
- Okada Y 1
- Sunada M 1
- Taki M 1
- Yamamura A 1
- Yamanoi K 1
2025
The combination therapy of lenvatinib plus pembrolizumab (LP) is increasingly recognized as an important second-line regimen for advanced or recurrent endometrial cancer (EC). However, the safety and efficacy of conversion surgery with low …